Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Cam Rising plays in Utah's spring football game after missing 2023 season with knee injuryChina's State Council appoints officialFeature: ChinaState Council meeting studies policies to sustain economic recoveryHamas says UNSC resolution demanding Gaza truce shows Israel's isolationXi extends congratulations to Yunnan University on centenary anniversaryXi stresses establishing new systems for higherSearch continues in Maine as officer is charged with lying about taking missing person to hospitalMainland spokesperson rebukes DPP for selling out Taiwan peopleXi presents order to promote military officers to rank of general
2.6584s , 6500.5703125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Interplay news portal